emm type | Geno, no. |
No. (%) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Erythromycin | Clindamycin | Tetracycline | Kanamycin | Streptomycin | Gentamicin | ||||||||||||||
S | R | S | iMLSB | cMLSB | S | R | S | R | S | R | S | R | |||||||
emm92 | ermT, 35 | 0 | 35 (100) |
0 | 31 (89) |
4 (11) |
0 | 35 (100) |
0 | 35 (100) |
0 | 35 (100) |
35 (100) |
0 | |||||
emm11 | ermA, 2 | 0 | 2 (100) |
0 | 2 (100) |
0 | 0 | 2 (100) |
0 | 2 (100) |
2 (100) |
0 | 2 (100) |
0 | |||||
ermB, 6 | 0 | 6 (100) |
0 | 3 (50) |
3 (50) |
6 (100) |
2 (33) |
4 (67) |
0 | 6 (100) |
6 (100) |
0 | |||||||
emm77 | ermA, 1 | 0 | 1 (100) |
0 | 1 (100) |
0 | 0 | 1 (100) |
0 | 1 (100) |
1 (100) |
0 | 1 (100) |
0 | |||||
ND, 1 | 1 (100) |
0 | 1 (100) |
0 | 0 | 1 (100) |
0 | 0 | 1 (100) |
1 (100) |
0 | 1 (100) |
0 | ||||||
emm83 | ermA, 3 | 0 | 3 (100) |
0 | 3 (100) |
0 | 0 | 3 (100) |
0 | 3 (100) |
2 (67) |
1 (33) |
3 (100) |
0 | |||||
emm197 | ermA, 1 | 0 | 1 (100) |
0 | 0 | 1 (100) |
0 | 1 (100) |
1 (100) |
0 | 1 (100) |
0 | 1 (100) |
0 | |||||
emm82 | ermB, 1 | 0 | 1 (100) |
0 | 0 | 1 (100) |
0 | 1 (100) |
1 (100) |
0 | 1 (100) |
0 | 1 (100) |
0 | |||||
emm22 | mefA, 1 | 0 | 1 (100) |
1 (100) |
0 | 0 | 0 | 1 (100) |
1 (100) |
0 | 1 (100) |
0 | 1 (100) |
0 | |||||
emm89 | ND, 5 | 5 (100) |
0 | 5 (100) |
0 | 0 | 5 (100) |
0 | NT | NT | 5 (100) |
0 | |||||||
emm† | ND, 10 | 10 (100) |
0 | 10 (100) |
0 | 0 | 9 (90) |
1 (10) |
2 (20) |
8 (80) |
9 (90) |
1 (10) |
10 (100) |
0 | |||||
Total = 66 | 16 (24) |
50 (76) |
17 (25) |
40 (61) |
9 (14) |
15 (23) |
51 (77) |
7 (11) |
54 (89) |
24 (39) |
37 (61) |
66 (100) |
0 |
Table 1. Phenotypic antimicrobial susceptibility results in invasive group A Streptococcus isolates, by emm type and resistance determinant, West Virginia, USA, 2020–2021*
*Geno, genotype; ND, resistance gene not detected; NT, not tested; R, resistant; S, susceptible.
†One emm11 isolate was not inducible by D-test but showed intermediate clindamycin resistance; other emm types with no erm: emm1 (2), emm2 (1), emm12 (1), emm28 (1), emm75 (1), emm81 (3), emm87 (1).
emm type | Kanamycin resistance | Streptomycin resistance | Tetracycline resistance | Determinant | Resistance element | Reference |
---|---|---|---|---|---|---|
emm92 | + | + | + | ICESpyM92, Tn916 | Tet(M), ant (6)-Ia, aph-(3′)-III | (5) |
pRW35 | ermT | (15) | ||||
emm11 | + | – | + | Tn6003-like | Tet(M), ermB, aph(3′)-III | (5) |
– | – | + | Tn6002 | Tet(M), ermB | (5) | |
+ | – | + | ICESp2905 | Tet(O), ermA, aph-(3′)-III | (21) | |
emm197 | – | – | + | ICESp2905 | Tet(O), ermA | (21) |
emm22 | – | – | + | Tn1207.1-like | Tet(O), mefA, | (20) |
Table 2. Proposed aminoglycoside and tetracycline resistance determinants in group A Streptococcus isolates, West Virginia, USA, 2020–2021
Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 1.00 ABIM MOC points
This activity is intended for infectious disease clinicians, internists, intensivists, public health officials, and other clinicians who treat and manage patients with invasive group A Streptococcus pyogenes (group A Streptococcus) infections.
The goal of this activity is for learners to be better able to describe the clinicoepidemiology of invasive group A Streptococcus pyogenes infections and the specific phenotypic and genotypic antimicrobial resistance traits of corresponding available isolates, based on a study of 76 invasive group A Streptococcus pyogenes isolates from 66 patients identified at J.W. Ruby Memorial Hospital in West Virginia from 2020 to 2021.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 4/14/2023
Valid for credit through: 4/14/2024
processing....
Clindamycin and β-lactam antibiotics have been mainstays for treating invasive group A Streptococcus (iGAS) infection, yet such regimens might be limited for strains displaying MLSB phenotypes. We investigated 76 iGAS isolates from 66 patients in West Virginia, USA, during 2020–2021. We performed emm typing using Centers for Disease Control and Prevention guidelines and assessed resistance both genotypically and phenotypically. Median patient age was 42 (range 23–86) years. We found 76% of isolates were simultaneously resistant to erythromycin and clindamycin, including all emm92 and emm11 isolates. Macrolide resistance was conferred by the plasmid-borne ermT gene in all emm92 isolates and by chromosomally encoded ermA, ermB, and a single mefA in other emm types. Macrolide-resistant iGAS isolates were typically resistant to tetracycline and aminoglycosides. Vulnerability to infection was associated with socioeconomic status. Our results show a predominance of macrolide-resistant isolates and a shift in emm type distribution compared with historical reports.
Streptococcus pyogenes, also known as group A Streptococcus (GAS), is a ubiquitous pathogen that produces an array of human disease, including focal infections (e.g., pharyngitis, pyoderma) with or without localized suppurative complications; invasive soft tissue infections (e.g., myositis, necrotizing fasciitis); and systemic, often fatal, infections (e.g., bacteremia, toxic shock syndrome). In addition, 2 postinfectious complications (glomerulonephritis and rheumatic heart disease) attributable to GAS have been well described[1–3]. Although GAS remains susceptible to penicillin, treatment with alternative or combination therapies, such as macrolides, clindamycin, and other second-line antimicrobial medications, is common because of patient β-lactam allergies, dosing convenience, infection severity, and patient acuity[4]. In contrast to its predictable β-lactam susceptibility, GAS resistance to other classes of antimicrobial drugs has been increasingly reported[5–7]. In the face of ongoing dissemination of the MLSB (macrolide, lincosamide, and streptogramin B) resistance phenotypes among GAS isolates, the Centers for Disease Control and Prevention (CDC) has labeled macrolide-resistant GAS an emerging threat of concern[8].
As 1 component of its Active Bacterial Core surveillance (ABCs) system, the CDC Emerging Infections Program, part of the National Center for Emerging and Zoonotic Infectious Diseases, Division of Preparedness and Emerging Infections, provides ongoing population-based assessments of GAS infections from 10 sites in the United States. Annual reports produced by the program estimate the incidence of invasive GAS (iGAS) infections within the United States doubled from 2009 to 2019; total numbers of infections increased from ≈11,000 cases (3.6 cases/100,000 population) to >25,000 cases (7.6 cases/100,000 population)[9,10]. Concomitant with this change, substantial increases in the proportion of iGAS isolates resistant to erythromycin and clindamycin have been reported; overall resistance rates climbed from <10% in 2010 to near 25% by 2017[11]. Populations at risk for such macrolide-resistant iGAS infections have been predominantly persons 18–64 years of age; incidence is high among persons with a history of intravenous drug use (IVDU) and persons experiencing homelessness[11,12].
West Virginia, USA, has seen a noticeable increase in annual rates of iGAS erythromycin resistance; at West Virginia University Medicine System (WVUMed) hospitals in Morgantown, rates increased from 37% in 2019 to 54% in 2020 and 87% in 2021. The state also has an extremely high per capita rate of drug overdose[13]. On the basis of all those considerations, we conducted a study to review clinicoepidemiology of iGAS infections within the region and to characterize specific phenotypic and genotypic antimicrobial resistance traits of corresponding available isolates.